Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants

This publication has 29 references indexed in Scilit:

• Malignant melanoma and renal cell carcinoma: Immunological and haematological effects of recombinant human interleukin-2
  European Journal of Cancer and Clinical Oncology, 1991
• Autoantibodies to cytokines - friends or foes?
  Immunology Today, 1990
• Interactions between cytokines and α2-macroglobulin
  Immunology Today, 1990
• Interleukin-1 receptor antagonist reduces mortality from endotoxin shock
  Nature, 1990
• Induction of Interferon‐β₂/Interleukin‐6 (IL‐6) by Cytokine Administration and Detection of Circulating Interleukin‐6 in the Tumor‐bearing State
  Annals of the New York Academy of Sciences, 1989
• Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
  New England Journal of Medicine, 1988
• Monocytic production and plasma bioactivities of interleukin‐1 and tumour necrosis factor in human cancer
  European Journal of Clinical Investigation, 1988
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer
  New England Journal of Medicine, 1987
• Interleukin 1 inhibitor masks high interleukin 1 production in acquired immunodeficiency syndrome (AIDS)
  Clinical Immunology and Immunopathology, 1987